Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
HOME > BUSINESS
BUSINESS
- Astellas Files Veozah in China for Menopausal VMS
October 28, 2026
- Lundbeck Japan Boosts Workforce 20% as It Revs Up Domestic Operations
October 28, 2026
- Forxiga Tops 8 Promotion Channels in September, Sweeps HP Market: Intage
October 28, 2026
- JB Banks on Sustained Aid to Double Plasma Processing Capacity
October 27, 2026
- Keytruda Tops Japan Drug Sales in April-September: Encise
October 27, 2026
- Japan Pharma Earnings Season Opens as Drug Price Cuts, Patent Cliffs Test Growth
October 27, 2026
- Takeda Opens New Kyoto Garden Area to Preserve Plants Used in Cultural Heritage
October 27, 2026
- Otsuka Ramps Up CVC Investments, Already Backs 2 Biotechs
October 27, 2026
- Medipal Shareholder Silchester Seeks Court Nod for Extraordinary Meeting
October 27, 2026
- NEC Joins European AI Vaccine Project for Pandemic Preparedness
October 27, 2026
- Mochida Kicks Off Japan PIII of Morning Sickness Drug
October 27, 2026
- Takeda-Innovent’s CLDN18.2 ADC Nets PIII Win in Gastric Cancer
October 27, 2026
- Wholesalers See NHI-Market Price Gap Falling Below 4.8% to New Record Low
October 26, 2026
- Vyepti Could Expand Migraine Treatment Options: Japanese Expert
October 26, 2026
- Zeria to Buy German Asacol Manufacturing Partner
October 26, 2026
- Otsuka’s IgAN Drug Voyxact Cuts Kidney Event Risk by 97%
October 26, 2026
- NEC’s Neoantigen Therapy Shows Immunogenicity in Early TNBC Trial
October 26, 2026
- Toho Subsidiary Faces Potential Data Leak via External Email Provider
October 26, 2026
- AbbVie Japan Rolls Out Rinvoq Oral Solution for Juvenile Arthritis
October 26, 2026
- EU Expands Padcev-Keytruda Use in Resectable MIBC
October 26, 2026
ページ
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…